Acorda acquires NeurogesX's pain patch and liquid for up to $12M

04/18/2013 | American City Business Journals

NeurogesX sold its Qutenza pain patch and an investigational liquid formulation called NGX-1998 to Acorda Therapeutics. NeurogesX will receive $7 million upfront, an additional $2 million if NGX-1998 wins FDA approval plus $3 million contingent on the drug's first-year sales hitting $100 million. The deal does not cover Europe, the Middle East or Africa, where Astellas Pharma holds marketing rights.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ